VolitionRx Limited (NYSEAMERICAN:VNRX), an epigenetics company developing diagnostic blood tests for humans and animals, announced Thursday that veterinarian Tom Butera has joined the company’s board of directors, effective December 1.
Butera was previously Chief Medical Officer of Pet Partners LLC, a chain of veterinary clinics that he founded, which was acquired by Mars Veterinary Health (MVH) in 2016. He currently serves as business development director at Veterinary Centers of America (VCA), which is also part of MVH.
He received his Bachelor of Arts degree from Fairfield University and his Doctorate of Veterinary Medicine from the University of Missouri Veterinary School.
"We are pleased to welcome Tom to the Volition board of directors," Chairman Martin Faulkes said in a statement. "Tom is a proven entrepreneur, innovator and value-based leader in the healthcare field, and we are confident he will bring a deep scientific understanding, as well as valuable strategic, operational and management experience at life science and veterinary companies to our board. This is a particularly timely appointment, given the launch of our Nu.Q Vet Cancer Screening Test earlier this week."
The Nu.Q Vet Cancer Screening Test is a low-cost, easy-to-use screening test that identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample. It is a less invasive diagnostic process.
"I am excited to join the board of a purpose-driven company that leads through innovation to enhance the health and well-being of people and pets," Butera said. "I look forward to working closely with my fellow directors and the Volition leadership team to deliver on our purpose while creating long-term value for our stakeholders."
Butera was also appointed to the company's audit, compensation and nominations and governance committees, the company said.
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel